Navigation Links
Skyline Diagnostics and Clavis Pharma to Collaborate on Patient Selection Biomarker Discovery for Leukemia Drug elacytarabine
Date:9/6/2011

ROTTERDAM, The Netherlands, September 6, 2011 /PRNewswire/ --

The Dutch biotech company Skyline Diagnostics B.V. (Skyline) and the Norwegian drug development company Clavis Pharma ASA (Clavis) disclosed signing a research agreement. Under this agreement, Skyline will investigate gene expression biomarkers for selection of individual Acute Myeloid Leukemia (AML) patients that may benefit from a new AML drug in development at Clavis. This drug, elacytarabine, is a novel elaidic acid derivative of cytarabine and currently undergoing the CLAVELA phase III study for treatment of patients with relapsed/refractory AML.

"For Clavis and for elacytarabine this is an important collaboration. Skyline Diagnostics's expertise will be instrumental in searching for gene expression patterns that can be utilized in the further biomarker program of elacytarabine," said Athos Gianella-Borradori, CMO of Clavis Pharma, "this genomic approach adds to our currently ongoing patient selection based on  protein markers and will deepen our insights into the potential for precise and highly effective personalized medicines. It is our goal and vision that this collaboration with the experts of Skyline will bring better therapies to the many patients suffering from difficult-to-treat leukemia."

"After the successful launch of the AMLprofiler in Europe, we are pleased to further strengthen our companion diagnostics activities," said Henk Viëtor, CEO of Skyline.

"Pharma companies are recognizing the value of companion diagnostics in positioning their drugs. By applying our bioinformatics engine, product development and regulatory experience, we can add substantial value to the process of drug development. We look forward working together with Clavis Pharma on this exciting personalized medicine opportunity."

About Skyline Diagnostics B.V.

Skyline Diagnostics develops and markets array-based diagnostic tests for personalized medicine. Skyline's
'/>"/>

SOURCE Skyline Diagnostics B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. SI-BONE, Inc. Closes $11.0 Million Financing Led by Skyline Ventures
2. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
6. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
7. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
10. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
11. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...   Ventana Medical Systems, Inc.  (Ventana), a ... its VENTANA System for Primary Diagnosis 1 ... for routine pathology, including primary diagnosis with human ... software coupled with either the VENTANA iScan Coreo ... automated digital slide creation, case management and computer ...
(Date:8/20/2014)... LYNDHURST, N.J. , Aug. 20, 2014  Amerigen ... Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA ... Mecobalamin 0.5 mg Tablets into the ... of a marketing and distribution agreement with Sinochem ... product at its US FDA approved and China ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 According ... filed on August 7 in the multicounty litigation (MCL) ... (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), ... MCL have been dismissed without prejudice. The cases enumerated ... process of being resolved.” The Rottenstein Law Group LLP, ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
(Date:8/20/2014)... Pittsburgh, PA (PRWEB) August 20, 2014 ... to clean the mouth in an optimal manner without ... an inventor from Vacaville, Calif. , The patent-pending DR. ... the tongue and teeth thoroughly. It promotes good oral ... to use two different devices. Convenient, compact, affordable, eco-friendly ...
(Date:8/20/2014)... Tumour Research has been chosen by Plymouth University to ... launched in April 2009 to raise awareness of, and ... outcomes for brain tumour patients. , A range of ... funds for the charity, and members of staff and ... encouraged to donate, fundraise and volunteer. The involvement of ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2
... Preventative Services Task Force,s (USPSTF) recommendation to no longer ... has begun to negatively affect the number of yearly ... the benefits of early detection. After the USPSTF delivered ... of Colorado saw a significant drop in mammograms in ...
... Mayo Clinic researchers have discovered two mutations responsible for ... ago. The researchers say their study -- appearing in ... neural pathway that may help understand a variety of ... now because of Next Generation genomic sequencing technology," says ...
... bursts of sleep in infants are linked with growth spurts, new ... daily sleep records for their infants (14 girls, nine boys), who ... researchers analyzed the total of 5,798 daily sleep records and also ... sleep, with the amount of sleep over a 24-hour period increasing ...
... can be quite jarring for a parent or caregiver to ... child roaming around the backseat free of their safety restraints. ... researchers reveals that most children who first unbuckle were age ... vehicle is in motionputting them at a 3.5-fold increased risk ...
... -- A drug commonly used to treat kidney cancer may ... study published in the May issue of the Journal ... the action of mammalian target of rapamycin (mTOR), a protein ... used to treat advanced renal cell carcinoma. But researchers ...
... Medical costs for children and teens with diabetes are six ... States, a new study finds. Researchers from the U.S. ... made in 2007 for nearly 50,000 youth aged 19 and ... youth with diabetes were $9,061, compared with $1,468 for those ...
Cached Medicine News:Health News:New studies show negative effects from revised mammography recommendation for women, ages 40-49 2Health News:Mayo Clinic finds new genetic cause of neurodegeneration 2Health News:Extra Sleep in Infants Seems to Signal Growth Spurts 2Health News:Little fingers, big trouble: Yale study sheds light on child self-unbuckling 2Health News:Renal cancer drug temsirolimus shows promise against mesothelioma 2
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
5L...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
Medicine Products: